ArticleFrontiers in oncology2025
Multi-isocentric volumetric arc-based total body irradiation: radiation dose impact on oncological outcomes in patients receiving allogeneic hematopoietic cell transplantation.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Total body irradiation (TBI) is an important component of conditioning schedules. Data comparing different radiotherapy (RT) regimens in allogeneic hematopoietic cell transplantation (allo-HCT) remain limited. We aimed to evaluate the oncological outcomes of patients receiving different RT doses. Materials and methods: All patients treated with multi-isocentric volumetric arc-based total body irradiation (VMAT-TBI) at a dose of ≥8 Grays (Gy) between 2021 and 2023 were included in this retrospective analysis. The RT regimens were either 8 Gy delivered in 4 bi-daily fractions (fx) or 12 Gy in 6 bi-daily fx. We evaluated the overall survival (OS), relapse-free survival (RFS), engraftment, and toxicities in both groups. Results: Forty-two patients met the inclusion criteria, including 24 treated with a 12 Gy regimen. Hazard ratio for OS after adjusting for age, Charlson Comorbidity Index (CCI), Disease Risk Index (DRI), disease status and total conditioning score (TCI) for survival was 0.02 (0.00, 0.48. p=0.01) in favor of a higher dose. The median RFS in the 12 Gy cohort was not achieved, and it was 11.8 months in the 8 Gy group. Toxicities were comparable between the groups. Two treatment-related deaths occurred in the 8 Gy arm. All patients in the 12 Gy arm achieved engraftment, whereas one graft failure was observed in the 8 Gy arm. Conclusion: In patients receiving modern TBI before allo-HCT with high-quality dose distribution, 12 Gy appears to be more effective than 8 Gy. However, this concerns a single-center cohort with TBI dose allocation according to estimated patient fragility before transplant. Therefore, randomized trials are required to determine the optimal RT dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.